Treatment of cancer-associated anaemia: Results from a two-day cross-sectional survey in Germany

Onkologie(Czech Republic)

Volumn 36, Issue 5, 2013, Pages 266-272

  Link, Hartmut ^a   Schmitz, Stephan ^b  

^a Westpfalz Klinikum GmbH   (Germany)

^b Onkologische Schwerpunktpraxis   (Germany)

Author keywords

Anaemia; Blood transfusion; Cancer; Erythropoietin; Iron

Indexed keywords

HEMOGLOBIN;

ADULT; AFTERCARE; AGED; ANEMIA; CANCER ASSOCIATED ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; GERMANY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; REVIEW; TREATMENT DURATION;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANEMIA; CAUSALITY; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; GERMANY; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878228573     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000350306     Document Type: Review

References (51)

1. Barrett-Lee P, Bokemeyer C, Gascon P, Nortier JW, Schneider M, Schrijvers D, Van Belle S: Management of cancer-related anemia in patients with breast or gynecologic cancer: New insights based on results from the European Cancer Anemia Survey. Oncologist 2005;10: 743-757.
2. Birgegard G, Gascon P, Ludwig H: Evaluation of anaemia in patients with multiple myeloma and lymphoma: Findings of the European Cancer Anaemia Survey. Eur J Haematol 2006;77: 378- 386.
3. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D: The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40: 2293- 2306.
4. Cella D: The effects of anemia and anemia treatment on the quality of life of people with cancer. Oncology (Williston Park) 2002;16: 125-132.
5. Demetri GD: Anaemia and its functional consequences in cancer patients: Current challenges in management and prospects for improving therapy. Br J Cancer 2001;84(suppl 1): 31-37.
6. Ludwig H, Strasser K: Symptomatology of anemia. Semin Oncol 2001;28: 7-14.
7. Dubray B, Mosseri V, Brunin F, Jaulerry C, Poncet P, Rodriguez J, Brugere J, Point D, Giraud P, Cosset JM: Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study. Radiology 1996;201: 553-558.
8. Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ Jr, Coia LR: Pretreatment hemoglobin level influences local control and survival of t1-t2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995;13: 2077-2083.
9. Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50: 705-715.
10. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19: 2865-2874.
11. Waters JS, O'Brien ME, Ashley S: Management of anemia in patients receiving chemotherapy. J Clin Oncol 2002;20: 601-603.
12. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40: 2201-2216.
13. Bokemeyer C, Oechsle K, Hartmann JT: Anaemia in cancer patients: Pathophysiology, incidence and treatment. Eur J Clin Invest 2005;35(suppl 3): 26- 31.
14. Steinmetz T, Totzke U, Soling U, Groschek M, Mittermuller J, Schweigert M, Tesch H, Nawka S, Schmitz S, Tsamaloukas A: Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia - examination of practice in Germany. Curr Med Res Opin 2008;24: 2751-2756.
15. Goodnough LT, Nemeth E, Ganz T: Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010;116: 4754-4761.
16. Churchhouse AM, Mathews TJ, McBride OM, Dunning J: Does blood transfusion increase the chance of recurrence in patients undergoing surgery for lung cancer? Interact Cardiovasc Thorac Surg 2012;14: 85-90.
17. Kim SH, Lee SI, Noh SM: Prognostic significance of preoperative blood transfusion in stomach cancer. J Gastric Cancer 2010;10: 196-205.
18. Vamvakas EC, Blajchman MA: Blood still kills: Six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010;24: 77-124.
19. Vamvakas EC, Blajchman MA: Transfusion-related mortality: The ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009;113: 3406-3417.
20. Acheson AG, Brookes MJ, Spahn DR: Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: A systematic review and meta-analysis. Ann Surg 2012;256: 235-244.
21. Amato A, Pescatori M: Perioperative blood transfusions and recurrence of colorectal cancer. Cochrane Database Syst Rev 2006;(1):CD005033.
22. Morgan TM, Barocas DA, Chang SS, Phillips SE, Salem S, Clark PE, Penson DF, Smith JA Jr, Cookson MS: The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol 2011, epub ahead of print, Sep 7.
23. Mortensen FV, Jensen LS, Sorensen HT, Pedersen L: Cause-specific mortality associated with leukoreduced, buffy coat-depleted, or no blood transfusion after elective surgery for colorectal cancer: A posttrial 15-year follow-up study. Transfusion 2011;51: 259-263.
24. Shiba H, Ishida Y, Wakiyama S, Iida T, Matsumoto M, Sakamoto T, Ito R, Gocho T, Furukawa K, Fujiwara Y, Hirohara S, Misawa T, Yanaga K: Negative impact of blood transfusion on recurrence and prognosis of hepatocellular carcinoma after hepatic resection. J Gastrointest Surg 2009;13: 1636-1642.
25. Steinmetz T, Hellmich M, Neise M, Aldaud A, Lerchenmuller C, Tsamaloukas A, Fandel F, Weiligmann C, Totzke U, Schmitz S: Prediction of the responsiveness to treatment with erythropoiesis- stimulating factors: A prospective clinical study in patients with solid tumors. Oncologist 2007;12: 748-755.
26. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE: Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26: 132-149.
27. Marchal C, Misset JL, Casadevall N, Marec- Berard P, Chastagner P, Kassab-Chahmi D, Ray- Coquard I: [Standards & options: Recommendations for the use of erythropoiesis-stimulating agents (ESA) in anaemic cancer patients undergoing radiotherapy (2007 update)]. Cancer Radiother 2008;12: 126-133.
28. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR; American Society of Clinical Oncology; American Society of Hematology: American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010; 28: 4996-5010.
29. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43: 258-270.
30. Ray-Coquard I, Kassab-Chahmi D, Casadevall N, Chastagner P, Marchal C, Marec-Berard P, Misset JL: [Clinical practice guidelines for the use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, darbepoetin) in anaemic patients with cancer: 2007 update (summary report)]. Bull Cancer 2008;95: 433-441.
31. Aapro MS, Link H: September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008; 13(suppl 3): 33-36.
32. de Benoist B, McLean E, Egli I, Cogswell M: Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia. Geneva, World Health Organisation, 2008.
33. Barrett-Lee PJ, Ludwig H, Birgegard G, Bokemeyer C, Gascon P, Kosmidis PA, Krzakowski M, Nortier JW, Kongable G, Schneider M, Schrijvers D, Van Belle SJ: Independent risk factors for anemia in cancer patients receiving chemotherapy: Results from the European Cancer Anaemia Survey. Oncology 2006;70: 34-48.
34. Vincent M, Dranitsaris G, Verma S, Lau C, Gascon P, Van Belle S, Ludwig H: The development and validation of a prediction tool for chemotherapy- induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy. Support Care Cancer 2007;15: 265- 272.
35. Kosmidis P, Krzakowski M: Anemia profiles in patients with lung cancer: What have we learned from the European Cancer Anaemia Survey (ECAS)? Lung Cancer 2005;50: 401-412.
36. Lyman GH, Crawford J, Kuderer NM, Wolff DA, Culakova E, Poniewierski MS, Dale DC: A conditional risk model for chemotherapy-induced anemia (CIA) in cancer patients. Blood 2007;110:abstr 372.
37. Boogaerts M, Oberhoff C, Ten Bokkel Huinink W, Nowrousian MR, Hayward CR, Burger HU: Epoetin beta (neorecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: A meta-analysis. Anticancer Res 2006;26: 479-484.
38. Coiffier B, Guastalla JP, Pujade-Lauraine E, Bastit P: Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: Results of a retrospective survey. Eur J Cancer 2001;37: 1617-1623.
39. Denison U, Baumann J, Peters-Engl C, Samonigg H, Krippl P, Lang A, Obermair A, Wagner H, Sevelda P: Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat 2003;79: 347-353.
40. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS: Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100: 2303-2320.
41. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE: Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008;111: 25-41.
42. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR; American Society of Hematology and the American Society of Clinical Oncology Practice Guideline Update Committee: American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010;116: 4045- 4059.
43. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 2004;22: 1301-1307.
44. Bundesärztekammer: Querschnittsleitlinien (BÄK) zur Therapie mit Blutkomponenten und Plasmaderivaten. www.baek.de/downloads/ Querschnittsleitlinie- Gesamtdokument-deutsch-07032011.pdf, Vorstand der Bundesärztekammer, 2008, pp 1-171.
45. Churchhouse AM, Mathews TJ, McBride OM, Dunning J: Does blood transfusion increase the chance of recurrence in patients undergoing surgery for lung cancer? Interact Cardiovasc Thorac Surg 2012;14: 85-90.
46. Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sokler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V: Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: Results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 2010;28: 2239-2245.
47. Delarue R, Haioun C, Fornecker L, Mounier M, Molina TJ, Bologna S, Fruchart C, Picard S, Tilly H, Bosly A: Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study. J Clin Oncol 2011; 29(suppl):abstr 9048.
48. Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Wurschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Mobus V, Hinke A, Kummel S, Budach V, Lichtenegger W, Schmid P: Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: Results of the NOGGO-AGO Intergroup Study. J Clin Oncol 2011;29: 3791-3797.
49. Nitz U, Gluz O, Oberhoff C, Reimer T, Schumacher C, Hackmann J, Warm M, Uleer C, Runde V, Kuemmel S, Zuna I, Harbeck N: Adjuvant chemotherapy with or without darbepoetin alpha in node-positive breast cancer: Survival and quality of life analysis from the prospective randomized WSG ARA trial. 34th Annual San Antonio Breast Cancer Symposium, San Antonio, 2011, abstr PD07-06.
50. Castillo JJ, Dalia S, Pascual SK: Association between red blood cell transfusions and development of non-Hodgkin lymphoma: A meta-analysis of observational studies. Blood 2010;116: 2897-2907.
51. Musallam KM, Tamim HM, Richards T, Spahn DR, Rosendaal FR, Habbal A, Khreiss M, Dahdaleh FS, Khavandi K, Sfeir PM, Soweid A, Hoballah JJ, Taher AT, Jamali FR: Preoperative anaemia and postoperative outcomes in non-cardiac surgery: A retrospective cohort study. Lancet 2011;378: 1396-1407.